Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue	$ 192,925	$ 153,612	$ 147,588
Cost of goods sold	69,133	51,821	41,801
Gross profit	123,792	101,791	105,787
Operating expenses:
Research and development	32,337	26,421	21,616
Clinical and regulatory affairs	16,215	15,418	13,243
Marketing and sales	107,759	78,213	73,411
General and administrative	41,044	29,581	26,663
Restructuring costs	11,093	0	0
Settlement costs	4,650	0	0
Contract termination and business acquisition expenses	5,768	5,071	0
Total operating expenses	218,866	154,704	134,933
Loss from operations	(95,074)	(52,913)	(29,146)
Other income (expense):
Interest income	228	175	245
Interest expense	(15,841)	(7,476)	(5,709)
Other income (expense), net	(2,161)	553	(5,798)
Change in fair value of contingent consideration related to acquisition	2,500	(100)	7,928
Change in fair value of derivative liabilities	(43,831)	0	0
Total other income (expense)	(59,105)	(6,848)	(3,334)
Net loss before income tax	(154,179)	(59,761)	(32,480)
Income tax benefit (expense)	(498)	9,337	62
Net loss	(154,677)	(50,424)	(32,418)
Other comprehensive income (loss) foreign currency translation	978	(1,762)	3,369
Comprehensive loss	$ (153,699)	$ (52,186)	$ (29,049)
Basic and diluted net loss per share (in USD per share)	$ (1.91)	$ (0.75)	$ (0.50)
Shares used in computing basic and diluted net loss per share (in shares)	80,976	67,671	65,225